TransMedics Group, Inc. (NASDAQ:TMDX) Receives $102.00 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $102.00.

TMDX has been the topic of a number of recent research reports. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Piper Sandler started coverage on shares of TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price on the stock. Oppenheimer raised their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th.

Insider Activity at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 4,000 shares of TransMedics Group stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Waleed H. Hassanein sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Gordon sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $85.45, for a total value of $1,281,750.00. Following the completion of the sale, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at approximately $1,117,258.75. The disclosure for this sale can be found here. Insiders have sold a total of 117,078 shares of company stock worth $9,972,971 over the last quarter. Company insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently bought and sold shares of the stock. Cutler Group LLC CA raised its stake in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares during the period. Global Retirement Partners LLC bought a new stake in TransMedics Group in the third quarter worth about $38,000. First Horizon Advisors Inc. boosted its stake in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares during the last quarter. RiverPark Advisors LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $60,000. Finally, Van ECK Associates Corp increased its stake in shares of TransMedics Group by 39.0% during the 3rd quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after purchasing an additional 597 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $86.51 on Thursday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $99.63. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock’s 50-day simple moving average is $82.85 and its 200 day simple moving average is $73.74. The firm has a market capitalization of $2.83 billion, a PE ratio of -112.35 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. During the same period in the previous year, the firm posted ($0.21) EPS. The firm’s revenue was up 158.6% on a year-over-year basis. On average, analysts anticipate that TransMedics Group will post -0.14 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.